X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Oxford leads first trial investigating dosing with alternating vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

    Pfizer’s new partnership focuses on digitising clinical trials

    Pfizer Invests $120 Million in Biotechnology Innovation

    DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

    Pfizer and BioNTech Announce Agreement with the UK 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

    Baxter Biopharma Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

Content Team by Content Team
5th June 2020
in Clinical Trials, News
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

FSD Pharma Inc. received approval from the U.S. FDA to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

Based on the FDA feedback, the trial will likely be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care (SOC) versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19. The primary endpoint is to determine if FSD-201 plus SOC provides a significant improvement in clinical status. Key secondary objectives include determining if FSD-201 plus SOC demonstrates additional benefit in terms of safety, objective assessments such as length of time to normalization of fever, length of time to improvement of oxygen saturation and length of time to clinical progression including time to mechanical ventilation or hospitalization, and length of hospital stay.

“FDA’s permission to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-201 is a paradigm shift for FSD Pharma and is the result of outstanding work conducted by Dr. Edward Brennan, President FSD BioSciences, and his team,” said Raza Bokhari, MD, Executive Co-Chairman & CEO. “We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultra micronized PEA for patients suffering from symptoms of COVID-19, based on the drug’s mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines. Numerous studies over the past 40 years also validate the efficacy and safety of ultra micronized PEA in the treatment and prophylactic effects in respiratory infections.”

Previous Post

Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients

Next Post

Vetter wins Axia Best Managed Company Award

Related Posts

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
CSafe Global to present new Parcel and Cell & Gene thermal shipping solutions
News

CSafe Global Continues Expansion Across Asia with Two New Hub Locations in China

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Bemis Healthcare Packaging introduces Insura seal verification technology
Featured

Partnership to Build Cold Chain Monitoring into Pharma Manufacturing, Packaging, Distribution

28th January 2021
Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance
Drug Development

Merck, Pfizer get EU nod for Bavencio as bladder cancer maintenance

28th January 2021
VirScan offers new insights into COVID-19 antibody response
News

Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study

28th January 2021
Next Post
Vetter wins Axia Best Managed Company Award

Vetter wins Axia Best Managed Company Award

Latest News

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Clinical Trials

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

4th February 2021
CSafe Global to present new Parcel and Cell & Gene thermal shipping solutions
News

CSafe Global Continues Expansion Across Asia with Two New Hub Locations in China

4th February 2021
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
Drug Development

GSK and CureVac to develop next generation mRNA COVID-19 vaccines

4th February 2021
Oxford leads first trial investigating dosing with alternating vaccines
Drug Development

Oxford leads first trial investigating dosing with alternating vaccines

4th February 2021
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Drug Development

Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

28th January 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In